Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
United Laboratories International Holdings (SEHK:3933) just released phase 2 data for UBT251, a triple agonist for type 2 diabetes, showing larger HbA1c and weight reductions compared with semaglutide and placebo in Chinese patients. See our latest analysis for United Laboratories International Holdings. Despite the strong UBT251 data and recent earnings release, the share price at HK$10.15 reflects a 1 month share price return decline of 21.92% and a 1 year total shareholder return decline...
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mgThe safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical tria
The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeksUBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies. Guangdong, China and Bagsværd, Denmark, 24 February 2026 – The United Laboratori
United Laboratories International Holdings recently announced the successful completion of a Phase II clinical trial for its TUL01101 Tablets, a JAK1 inhibitor, in treating moderate-to-severe atopic dermatitis in adults, showing significant efficacy and a positive safety profile. This progress highlights the group’s advancing pipeline in the autoimmune disease treatment market, with the Phase III trial set to launch in China. We’ll explore how the move toward Phase III trials for TUL01101...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.